The marathon surgical session, conducted between 8 am and 5 pm, was led by Dr (prof) Santosh Kumar, with the procedures ...

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

Fatigue assessment when treatment is started may be an early clinical marker of adverse event risk, the researchers suggested ...

Liv Hospital integrates PET/CT diagnostics, radionuclide therapies and a multidisciplinary council to create individualized treatment plans for complex cancer and cardiac cases.

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

Neighborhood-level social determinants of health were associated with varying cancer risks and greater mortality among kidney ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Researchers identify APOC1 and NOP16 as promising prostate cancer biomarkers that could aid early diagnosis. Learn more about ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

Nigeria has recorded a major milestone in cancer care with the introduction of High Intensity Focused Ultrasound (HIFU) ...

While the idea of getting “snipped” is painful for some men to even think about, actually having a vasectomy may lead to more ...